Search

Objective: To develop a French Short Version of the Questionnaire of Olfactory Disorders-Negative Statements (Fr-sQOD) to assess the quality of life impairments of patients with olfactory dysfunction (OD). Methods: Patients with OD and controls were enrolled from 2 academic centers. Individuals completed the Fr-sQOD, an OD visual analog scale severity, and the French version of the sinonasal outcome tool-22 (SNOT-22). Cronbach α was used to measure the internal consistency of Fr-sQOD. The reliability and the external validity of Fr-sQOD were assessed through a test–retest approach and by correlating Fr-sQOD with SNOT-22 scores, respectively. The external validity was assessed by correlation analysis between Fr-sQOD and the result of an assessment of the severity of OD on a visual analog scale. Results: Eighty patients completed the evaluations. The internal consistency was adequate (Cronbach α.96), and the test–retest reliability was high in the entire cohort (rs = 0.877, P <.001). The correlation between Fr-sQOD total scores and the severity of OD was moderate but significant (rs = −0.431; P =.001) supporting an acceptable external validity. Patients with OD had a significantly higher score of Fr-sQOD than healthy individuals (P <.001), indicating a high internal validity. Conclusion: The Fr-sQOD is a reliable and valid self-administered tool in the evaluation of the impact of OD on quality of life of French-speaking patients. [ABSTRACT FROM AUTHOR]

Objective: To evaluate the evolution of voice quality in patients after type I‐VI transoral CO2 laser cordectomy (TLC) by using validated voice outcome measures over a 12‐month period. Study Design: Prospective uncontrolled study. Setting: Monocenter study. Methods: Patients with laryngeal carcinoma who were eligible for type I‐IV TLC were prospectively recruited from a tertiary medical center. The following outcomes were assessed throughout the 12‐month posttreatment period: Voice Handicap Index (VHI), GRBAS (grade of dysphonia, roughness, breathiness, asthenia, strain), maximal phonation time, fundamental frequency (F0), F0 standard deviation, percentage jitter, percentage shimmer, noise‐to‐harmonic ratio, and speech fluency. Analyses were performed considering 2 groups of cordectomies: type I‐III vs IV‐VI. Results: A total of 131 patients completed the evaluations, totaling 76 type I‐III and 55 type IV‐VI cordectomies. In type IV‐VI, breathiness and maximal phonation time significantly worsened from pretreatment to 1 month posttreatment (P <.05). In the type I‐III cordectomy group, VHI, shimmer, roughness, breathiness, and strain significantly improved from pretreatment to 3 months posttreatment, while VHI, F0 standard deviation, shimmer, jitter, grade of dysphonia, roughness, breathiness, and strain improved from baseline to 6 months. Assessments at 12 months posttreatment revealed significant improvements for VHI, shimmer, jitter, noise‐to‐harmonic ratio, grade of dysphonia, roughness, breathiness, and strain. In the type IV‐VI group, VHI significantly improved from baseline to 3, 6, and 12 months posttreatment. Strain improved at 6 and 12 months while roughness improved from baseline to 12 months. Maximal phonation time significantly worsened over the 12‐month evaluation period. Conclusion: The effect of TLC on voice quality depends on its type. VHI was identified as the most indicative tool of voice changes irrespective of TLC type. [ABSTRACT FROM AUTHOR]

Objectives/Hypothesis: To compare the 12‐month evolution of voice quality outcomes in patients who benefited from types 1–2 transoral CO2 laser cordectomy (TLC) for an early‐stage vocal fold squamous cell carcinoma (VFSCC). Study Design: Prospective uncontrolled study. Methods: Sixty patients with cT1 VFSCC were consecutively recruited from a single medical center. Thirty patients benefited from type 1 TLC, while type 2 TCL was performed in 30 patients. The following voice quality outcomes were evaluated at baseline, 3‐, 6‐, and 12‐month post‐TLC: voice handicap index (VHI), GRBAS, speech rate, maximum phonation time (MPT), and acoustic parameters. Voice quality evolution was compared between type 1 and type 2 TLC. Results: Fifty‐seven patients completed the evaluations. Type 1 TLC patients reported significant improvements of VHI, grade of dysphonia, and breathiness at 3‐, 6‐, and 12‐month post‐TLC. Speech rate and jitter values improved 6‐ and 12‐month post‐TLC. A few voice quality outcomes reported 3‐ or 6‐month post‐TLC improvements in type 2 TLC group, while VHI, grade of dysphonia improved at 6‐ and 12‐month post‐TLC. MPT significantly decreased at 6‐ and 12‐month post‐TLC, while there were no acoustic measurement changes in type 2 TLC. Conclusions: The effect of TLC on voice quality may depend on the type of TLC. Type 1 TLC was associated with faster voice quality improvements compared with type 2 TLC. VHI and dysphonia grade were identified as the most relevant tool of voice changes irrespective to the TLC type. Level of Evidence: 3 Laryngoscope, 132:1421–1426, 2022 [ABSTRACT FROM AUTHOR]

To explore the prevalence of dysphonia in European patients with mild-to-moderate COVID-19 and the clinical features of dysphonic patients. The clinical and epidemiological data of 702 patients with mild-to-moderate COVID-19 were collected from 19 European Hospitals. The following data were extracted: age, sex, ethnicity, tobacco consumption, comorbidities, general, and otolaryngological symptoms. Dysphonia and otolaryngological symptoms were self-assessed through a 4-point scale. The prevalence of dysphonia, as part of the COVID-19 symptoms, was assessed. The outcomes were compared between dysphonic and nondysphonic patients. The association between dysphonia severity and outcomes was studied through Bayesian analysis. A total of 188 patients were dysphonic, accounting for 26.8% of cases. Females developed more frequently dysphonia than males (P = 0.022). The proportion of smokers was significantly higher in the dysphonic group (P = 0.042). The prevalence of the following symptoms was higher in dysphonic patients compared with nondysphonic patients: cough, chest pain, sticky sputum, arthralgia, diarrhea, headache, fatigue, nausea, and vomiting. The severity of dyspnea, dysphagia, ear pain, face pain, throat pain, and nasal obstruction was higher in dysphonic group compared with nondysphonic group. There were significant associations between the severity of dysphonia, dysphagia, and cough. Dysphonia may be encountered in a quarter of patients with mild-to-moderate COVID-19 and should be considered as a symptom list of the infection. Dysphonic COVID-19 patients are more symptomatic than nondysphonic individuals. Future studies are needed to investigate the relevance of dysphonia in the COVID-19 clinical presentation. [ABSTRACT FROM AUTHOR]

Objectives/Hypothesis: To investigate the surgical, oncological, and functional outcomes of transoral robotic surgery (TORS) for the treatment of supraglottic squamous cell carcinoma. Study Design: Retrospective chart review. Methods: The charts of patients treated by TORS supraglottic laryngectomy (SGL) in an academic medical center were reviewed. The following outcomes were studied according to the tumor location: average robotic setup and operative times, mean estimated blood loss, postoperative complications, need of tracheotomy, refeeding characteristics, mean hospital stay, need of neck dissection and adjuvant therapy, 5‐year local and regional controls, overall survival (OS), and disease‐free survival (DFS). Results: Seventy‐five patients underwent TORS SGL. Tumors were classified as cT1 (32%), cT2 (52%), and cT3 (16%). Average robotic setup and operative times and the mean estimated blood loss were 15 minutes, 55 minutes, and 20 mL, respectively. The mean follow‐up period ranged from 2 to 5 years. The 5‐year OS and DFS were 80.2% and 94.3%, respectively. Overall, 34.6% of patients received adjuvant radiotherapy. The majority of patients (92%) restarted an oral diet within 24 to 48 hours postsurgery. Transient tracheotomy was performed in 8% of patients. Postoperative hemorrhages occurred in 12 patients (16.0%), lengthening the hospital stay (mean = 6.8 days). There were no outcome differences regarding the tumor location. Conclusions: TORS is an effective and safe therapeutic approach for early‐ and intermediate‐stages cancers. Oncological outcomes may be quite similar to other surgical approaches, including transoral laser and open surgeries. Future randomized controlled studies are needed for comparing TORS SGL with other surgical procedures. Level of Evidence: 4 Laryngoscope, 131:1060–1065, 2021 [ABSTRACT FROM AUTHOR]

Medialization laryngoplasty with autologous fat (MLA) is indicated in some patients with glottic insufficiency. The approach is usually safe but long-term complications are poorly described. We present the history of a patient who developed progressive dyspnea and dysphonia two decades after bilateral MLA, which were due to the development of laryngea lipoma into the site of fat injection. The potential relationship between MLA and the development of laryngeal lipoma was discussed. The lipoma may be a long-term survival of too much fat tissue, which was reorganized into a well-limited lipoma over the long-term. Another hypothesis consisted of the injection of fat tissue, including fatty stem cells, and the development of a lipoma over the year through the neovascularization process. We reported the first case of lipoma developed into the laryngeal site of fat injection. Future studies are needed to explore the long-term evolution of injected fat tissue in the context of MLA. [ABSTRACT FROM AUTHOR]

• COVID-19 patients with total loss of smell have more olfactory bulb abnormalities at the magnetic resonance imaging than patients without loss of smell. • The olfactory bulb MRI abnormalities may be objectified through a signal intensity ratio measurement that is calculated between the average signals of the olfactory bulb and the frontal white matter. • The loss of smell is probably due to olfactory bulb inflammation related to virus spread. [ABSTRACT FROM AUTHOR]

Objective: To develop a French Short Version of the Questionnaire of Olfactory Disorders-Negative Statements (Fr-sQOD) to assess the quality of life impairments of patients with olfactory dysfunction (OD)., Methods: Patients with OD and controls were enrolled from 2 academic centers. Individuals completed the Fr-sQOD, an OD visual analog scale severity, and the French version of the sinonasal outcome tool-22 (SNOT-22). Cronbach α was used to measure the internal consistency of Fr-sQOD. The reliability and the external validity of Fr-sQOD were assessed through a test-retest approach and by correlating Fr-sQOD with SNOT-22 scores, respectively. The external validity was assessed by correlation analysis between Fr-sQOD and the result of an assessment of the severity of OD on a visual analog scale., Results: Eighty patients completed the evaluations. The internal consistency was adequate (Cronbach α .96), and the test-retest reliability was high in the entire cohort (r s = 0.877, P < .001). The correlation between Fr-sQOD total scores and the severity of OD was moderate but significant (r s = -0.431; P = .001) supporting an acceptable external validity. Patients with OD had a significantly higher score of Fr-sQOD than healthy individuals ( P < .001), indicating a high internal validity., Conclusion: The Fr-sQOD is a reliable and valid self-administered tool in the evaluation of the impact of OD on quality of life of French-speaking patients., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Objective: To evaluate the evolution of voice quality in patients after type I-VI transoral CO 2 laser cordectomy (TLC) by using validated voice outcome measures over a 12-month period., Study Design: Prospective uncontrolled study., Setting: Monocenter study., Methods: Patients with laryngeal carcinoma who were eligible for type I-IV TLC were prospectively recruited from a tertiary medical center. The following outcomes were assessed throughout the 12-month posttreatment period: Voice Handicap Index (VHI), GRBAS (grade of dysphonia, roughness, breathiness, asthenia, strain), maximal phonation time, fundamental frequency (F0), F0 standard deviation, percentage jitter, percentage shimmer, noise-to-harmonic ratio, and speech fluency. Analyses were performed considering 2 groups of cordectomies: type I-III vs IV-VI., Results: A total of 131 patients completed the evaluations, totaling 76 type I-III and 55 type IV-VI cordectomies. In type IV-VI, breathiness and maximal phonation time significantly worsened from pretreatment to 1 month posttreatment (P < .05). In the type I-III cordectomy group, VHI, shimmer, roughness, breathiness, and strain significantly improved from pretreatment to 3 months posttreatment, while VHI, F0 standard deviation, shimmer, jitter, grade of dysphonia, roughness, breathiness, and strain improved from baseline to 6 months. Assessments at 12 months posttreatment revealed significant improvements for VHI, shimmer, jitter, noise-to-harmonic ratio, grade of dysphonia, roughness, breathiness, and strain. In the type IV-VI group, VHI significantly improved from baseline to 3, 6, and 12 months posttreatment. Strain improved at 6 and 12 months while roughness improved from baseline to 12 months. Maximal phonation time significantly worsened over the 12-month evaluation period., Conclusion: The effect of TLC on voice quality depends on its type. VHI was identified as the most indicative tool of voice changes irrespective of TLC type., (© 2022 American Academy of Otolaryngology-Head and Neck Surgery Foundation.)

Objectives/hypothesis: To compare the 12-month evolution of voice quality outcomes in patients who benefited from types 1-2 transoral CO 2 laser cordectomy (TLC) for an early-stage vocal fold squamous cell carcinoma (VFSCC)., Study Design: Prospective uncontrolled study., Methods: Sixty patients with cT1 VFSCC were consecutively recruited from a single medical center. Thirty patients benefited from type 1 TLC, while type 2 TCL was performed in 30 patients. The following voice quality outcomes were evaluated at baseline, 3-, 6-, and 12-month post-TLC: voice handicap index (VHI), GRBAS, speech rate, maximum phonation time (MPT), and acoustic parameters. Voice quality evolution was compared between type 1 and type 2 TLC., Results: Fifty-seven patients completed the evaluations. Type 1 TLC patients reported significant improvements of VHI, grade of dysphonia, and breathiness at 3-, 6-, and 12-month post-TLC. Speech rate and jitter values improved 6- and 12-month post-TLC. A few voice quality outcomes reported 3- or 6-month post-TLC improvements in type 2 TLC group, while VHI, grade of dysphonia improved at 6- and 12-month post-TLC. MPT significantly decreased at 6- and 12-month post-TLC, while there were no acoustic measurement changes in type 2 TLC., Conclusions: The effect of TLC on voice quality may depend on the type of TLC. Type 1 TLC was associated with faster voice quality improvements compared with type 2 TLC. VHI and dysphonia grade were identified as the most relevant tool of voice changes irrespective to the TLC type., Level of Evidence: 3 Laryngoscope, 132:1421-1426, 2022., (© 2021 The American Laryngological, Rhinological and Otological Society, Inc.)